Drug Trial Radar · NCT06272487
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
375
Actual
Start
Feb 29, 2024
Primary completion
Jun 19, 2025
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Feb 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Conditions
- High Cardiovascular Risk
- Hypertension
Interventions
ZilebesiranDrug
Zilebesiran administered by subcutaneous (SC) injection
PlaceboDrug
Placebo administered by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline at Month 3 in Mean Seated Office Systolic Blood Pressure (SBP)Time frame: Baseline and Month 3
Locations
195 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Alexander City, Alabama
Clinical Trial Site
Daphne, Alabama
Clinical Trial Site
Foley, Alabama
Clinical Trial Site
Huntsville, Alabama
Clinical Trial Site
Huntsville, Alabama
Clinical Trial Site
Montgomery, Alabama
Clinical Trial Site
Gilbert, Arizona
Clinical Trial Site
Phoenix, Arizona
Clinical Trial Site
Sun City, Arizona
Clinical Trial Site
Tempe, Arizona
Clinical Trial Site
Tucson, Arizona
Clinical Trial Site
Beverly Hills, California
Clinical Trial Site
Covina, California
Clinical Trial Site
Encinitas, California
Clinical Trial Site
Garden Grove, California
Clinical Trial Site
Huntington Beach, California
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Northridge, California
Clinical Trial Site
Northridge, California
Clinical Trial Site
Pasadena, California
Clinical Trial Site
San Diego, California
Clinical Trial Site
San Diego, California
Clinical Trial Site
San Dimas, California
Clinical Trial Site
Simi Valley, California
Clinical Trial Site
Vacaville, California
Clinical Trial Site
Van Nuys, California
Clinical Trial Site
West Hills, California
Clinical Trial Site
Colorado Springs, Colorado
Clinical Trial Site
Denver, Colorado
Clinical Trial Site
Denver, Colorado
Clinical Trial Site
Hartford, Connecticut
Clinical Trial Site
Middlebury, Connecticut
Clinical Trial Site
Waterbury, Connecticut
Clinical Trial Site
Washington D.C., District of Columbia
Clinical Trial Site
Clearwater, Florida
Clinical Trial Site
Coral Gables, Florida
Clinical Trial Site
Daytona Beach, Florida
Clinical Trial Site
Fort Myers, Florida
Clinical Trial Site
Hollywood, Florida
Showing 40 of 195 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.